Kathryn Bylow

1.3k total citations
38 papers, 890 citations indexed

About

Kathryn Bylow is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Kathryn Bylow has authored 38 papers receiving a total of 890 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 10 papers in Surgery. Recurrent topics in Kathryn Bylow's work include Prostate Cancer Treatment and Research (12 papers), Bladder and Urothelial Cancer Treatments (10 papers) and Renal cell carcinoma treatment (9 papers). Kathryn Bylow is often cited by papers focused on Prostate Cancer Treatment and Research (12 papers), Bladder and Urothelial Cancer Treatments (10 papers) and Renal cell carcinoma treatment (9 papers). Kathryn Bylow collaborates with scholars based in United States, Australia and Austria. Kathryn Bylow's co-authors include Walter M. Stadler, Supriya G. Mohile, William Dale, Miriam Rodin, Daniel P. Petrylak, Karen M. Mustian, William J. Hall, James J. Dignam, Mark S. Lachs and Hedy L. Kindler and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Kathryn Bylow

33 papers receiving 871 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kathryn Bylow United States	14	400	367	245	212	129	38	890
Carmen L. Wilson United States	24	160 0.4×	370 1.0×	147 0.6×	256 1.2×	92 0.7×	63	1.6k
Trevor A. Jolly United States	14	252 0.6×	460 1.3×	378 1.5×	314 1.5×	69 0.5×	32	953
A.N.M. Wymenga Netherlands	19	240 0.6×	617 1.7×	244 1.0×	194 0.9×	101 0.8×	41	1.1k
Supriya Gupta India	6	100 0.3×	209 0.6×	300 1.2×	205 1.0×	59 0.5×	19	588
Jean Pierre Droz France	15	217 0.5×	235 0.6×	91 0.4×	137 0.6×	574 4.4×	24	1.0k
Francesco Rosetti Italy	13	437 1.1×	640 1.7×	149 0.6×	120 0.6×	139 1.1×	23	1.1k
Tracey L. O’Connor United States	17	332 0.8×	944 2.6×	64 0.3×	77 0.4×	94 0.7×	59	1.4k
Angela Wu United States	18	523 1.3×	149 0.4×	115 0.5×	28 0.1×	258 2.0×	45	1.0k
Suzanne Stewart United States	14	565 1.4×	210 0.6×	129 0.5×	232 1.1×	343 2.7×	30	1.0k
Donald Poon Singapore	10	103 0.3×	314 0.9×	141 0.6×	120 0.6×	84 0.7×	14	774

Countries citing papers authored by Kathryn Bylow

Since Specialization

Citations

This map shows the geographic impact of Kathryn Bylow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathryn Bylow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathryn Bylow more than expected).

Fields of papers citing papers by Kathryn Bylow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathryn Bylow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathryn Bylow. The network helps show where Kathryn Bylow may publish in the future.

Co-authorship network of co-authors of Kathryn Bylow

This figure shows the co-authorship network connecting the top 25 collaborators of Kathryn Bylow. A scholar is included among the top collaborators of Kathryn Bylow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathryn Bylow. Kathryn Bylow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thapa, Bicky, Aditya Shreenivas, Kathryn Bylow, et al.. (2024). Successful Targeting of Somatic VHL Alterations With Belzutifan in Two Cases. SHILAP Revista de lepidopterología. 7(4). 308–313. 1 indexed citations

Kamaraju, Sailaja, June M. McKoy, Grant R. Williams, et al.. (2024). An Annual Symposium on Disparities in Milwaukee, WI, with a 2023 Focus on Older Adults with Cancer. Current Oncology Reports. 26(8). 855–864.

Graff, Julie N., Mauricio Burotto, Peter C.C. Fong, et al.. (2023). 1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study. Annals of Oncology. 34. S957–S957. 13 indexed citations

Nelson, Ariel Ann, et al.. (2023). Impact of pre-treatment hemoglobin (Hgb) on outcomes in metastatic castration resistant prostate cancer (mCRPC) with lutetium-177-PSMA-617 (Lu-177).. Journal of Clinical Oncology. 41(16_suppl). e17065–e17065.

Hall, William A., Meena Bedi, Deepak Kilari, et al.. (2021). Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial. Practical Radiation Oncology. 11(6). 527–533. 4 indexed citations

Kilari, Deepak, Jason Zittel, Arpan Patel, et al.. (2020). 677P A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Final analysis. Annals of Oncology. 31. S540–S541. 1 indexed citations

Milowsky, Matthew I., Nancy B. Davis, Chunkit Fung, et al.. (2020). 801TiP A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE). Annals of Oncology. 31. S607–S607. 2 indexed citations

Sahasrabudhe, Deepak M., Elizabeth A. Guancial, Kathryn Bylow, et al.. (2020). The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020?. Clinical Genitourinary Cancer. 18(4). e478–e483. 6 indexed citations

Lea, William, et al.. (2020). Outcomes With Liver-Directed Therapy for Genitourinary Malignancies: Single-Institution Experience. Clinical Genitourinary Cancer. 19(1). 87–91.

10.

Riese, Matthew J., Kathryn Bylow, Alexander C. Mackinnon, et al.. (2017). Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm. Clinical Genitourinary Cancer. 15(5). e897–e901. 15 indexed citations

11.

Grivas, Petros, Stephanie Daignault, Scott T. Tagawa, et al.. (2013). Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 120(5). 692–701. 75 indexed citations

12.

Bylow, Kathryn, et al.. (2011). Obese Frailty, Physical Performance Deficits, and Falls in Older Men with Biochemical Recurrence of Prostate Cancer on Androgen Deprivation Therapy: A Case-control Study. Urology. 77(4). 934–940. 57 indexed citations

13.

Ramsdale, Erika, Blasé N. Polite, Kathryn Bylow, Hedy L. Kindler, & William Dale. (2011). Relationship between components of the comprehensive geriatric assessment (CGA), chemotherapy dose intensity, and overall survival in a colorectal cancer (CRC) cohort age 65 and older.. Journal of Clinical Oncology. 29(15_suppl). 9000–9000. 6 indexed citations

14.

Mohile, Supriya G., Maureen Lacy, Miriam Rodin, et al.. (2010). Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Critical Reviews in Oncology/Hematology. 75(2). 152–159. 53 indexed citations

15.

Mohile, Supriya G., Karen M. Mustian, Kathryn Bylow, William J. Hall, & William Dale. (2008). Management of complications of androgen deprivation therapy in the older man. Critical Reviews in Oncology/Hematology. 70(3). 235–255. 47 indexed citations

16.

Mohile, Supriya G., Kathryn Bylow, William Dale, et al.. (2007). A pilot study of the vulnerable elders survey‐13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer. 109(4). 802–810. 186 indexed citations

17.

Bylow, Kathryn, Supriya G. Mohile, Walter M. Stadler, & William Dale. (2007). Does androgen‐deprivation therapy accelerate the development of frailty in older men with prostate cancer?. Cancer. 110(12). 2604–2613. 103 indexed citations

18.

Kindler, Hedy L. & Kathryn Bylow. (2007). Pancreatic cancer: An update. Current Oncology Reports. 9(3). 170–176. 26 indexed citations

19.

Ryan, Christopher W., Dezheng Huo, Kathryn Bylow, et al.. (2007). Suppression of bone density loss and bone turnover in patients with hormone‐sensitive prostate cancer and receiving zoledronic acid. British Journal of Urology. 100(1). 70–75. 52 indexed citations

20.

Kindler, Hedy L., Kathryn Bylow, H. S. Hochster, et al.. (2006). A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis. Journal of Clinical Oncology. 24(18_suppl). 4040–4040. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact